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Background:  Deep venous thrombosis (DVT) portends a poor prognosis in patients with cancer. The treatment of choice has been low 
molecular weight heparins ( LMWH). Due to presence of resistance, warfarin is not the preferred anticoagulant . There is a paucity of data 
on the use of new oral anticoagulants (NOAC) in this setting. Chronic subcutaneous injection of LMWH is cumbersome and inconvenient. 
We report on the role of NOAC in patients with cancer- related lower extremity (LE) DVT who received rivaroxaban and apixaban following 
percutaneous endovenous intervention (PEVI). 
methods:  Following PEVI , a NOAC at modified dose was given to 65 patients with cancer who had developed extensive symptomatic LE 
DVT. DVT was bilateral in 21 patients (32%). At the time of DVT, 18 patients (28%) were on warfarin of whom 9 had therapeutic INR (50%). 
PEVI was performed within 26±4 hours of admission. Heparin was given to all on presentation and was discontinued after completion of 
PEVI. Two hours after completion of PEVI, a modified dose of NOAC was initiated and continued indefinitely. Rivaroxaban was given at 
20 mg daily and apixaban at 5 mg twice daily. Warfarin was stopped in those who were on it. The mean follow up was 18±3months. The 
patients were evaluated for mortality, recurrent venous thromboembolic disease (VTE), post- thrombotic syndrome (PTS) and bleeding 
during this period. 
results:  There were 5 deaths due to cancer at follow-up.There was no bleeding or recurrent VTE in any patient. PTS developed in 4 
patients (6%) with a mean Vllalta score of 6.25 indicative of only mild severity. The mean duration of hospitalization was 32±3 hours. The 
anticoagulation regimen was tolerated in all patients. 
conclusion:  Administration of NOAC following PEVI is highly safe and effective in cancer associated DVT. This approach leads to a short 
duration of hospitalization and no early or late bleeding or recurrent VTE. Development of PTS is infrequent and is of only mild severity.
Patient satisfaction is greater as the inconveniences associated with chronic subcutaneous anticoagulation with LMWHs are eliminated.
